Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Honest Company Inc (HNST) vs Neurocrine Biosciences Inc (NBIX) Price & Performance

Honest Company IncTrade
Neurocrine Biosciences IncTrade

Price performance (Past 24H)

Key statistics

Honest Company Inc vs Neurocrine Biosciences Inc — how do they compare? Honest Company Inc trades at $5.13 (market cap $558.95M), while Neurocrine Biosciences Inc trades at $156.95 (market cap $16.46B). The key difference: Neurocrine Biosciences Inc is far larger — about 29.4× Honest Company Inc's market cap, and Honest Company Inc is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.

HNSTNBIX
Market Cap
$558.95M$16.46B
Sector
Consumer StaplesHealth
52-Week High
$5.46$185.50
52-Week Low
$2.10$123.10
Enterprise Value
$462.56M$16.48B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Honest Company Inc

HNST trades at $5.21, down 0.38% on the day, with a bullish technical signal from moving averages despite overbought RSI readings. The company reported mixed Q2 2026 results with an earnings beat but declining revenue, while maintaining negative profitability metrics including a -3.56% net income margin. Recent strategic exits have impacted top-line performance but improved underlying profitability trends.

The stock faces headwinds from inconsistent earnings performance and negative margins, though improved cash flow and strategic repositioning offer potential upside. Analyst sentiment remains cautious with 30% buy ratings, reflecting concerns about sustained profitability amid ongoing business transformation efforts.

Neurocrine Biosciences Inc

Neurocrine Biosciences (NBIX) trades at $156.95, down 4.83% in the last session, with a bearish technical signal from moving averages and ADX. The stock shows strong fundamentals, including a 39% year-over-year revenue growth in Q2 2026 to $959 million and a net income margin of 20.91% for 2026. Recent developments include positive INGREZZA clinical data and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.

The outlook for NBIX is positive with a consensus price target of $208.82, implying 33% upside, supported by robust earnings beats and portfolio expansion. Risks include drug safety issues, competitive pressures, and reliance on INGREZZA sales. Investors should weigh strong analyst bullishness against regulatory and execution risks in the biopharmaceutical sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Honest Company Inc

The Honest Co Inc is a consumer products company. It offers eco-friendly diapers and a natural line of bath, skincare, home cleaning, and organic nutritional supplement products and other products.

Read more on HNST

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Read more on NBIX